AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
